Abstract 1681P
Background
Adjuvant chemotherapy offers patients an improved chance of long-term survival, especially for those with R0/R1 resection. In APACT study, the median overall survival (mOS) of adjuvant chemotherapy for resectable pancreatic cancer (RPC) patients ranged from 36.2 to 40.5 months, but further improvement is still needed. As targeted therapy is still a blank in the treatment of RPC, we conducted this study, aiming to explore the clinical benefit of the addition of nimotuzumab to standard adjuvant chemotherapy.
Methods
RPC patients were treated with surgery, postoperative chemotherapy with or without nimotuzumab. Demographic and clinical data were collected from electronic medical records of Ruijin Hospital from May 2016 to July 2022. The primary efficacy endpoint was OS.
Results
We identified 795 patients who underwent surgical resection, of which 57 RPC patients received nimo. Propensity score matching (PSM) was performed to reduce the bias. After 1:1 PSM, we created 32 pairs RPC patients (stage I and II) who received adjuvant chemotherapy with nimo (study arm, Nimotuzumab 400mg, weekly, median exposure was 4 weeks) or without (control arm). Baseline characteristics were balanced after PSM. Median age was 63y, with 66% males. Barthel score 80-100. Median follow-up time was 35.2 (95%CI, 24.8-57.4) months and 37.3 (95%CI, 21.6-42.8) months in the control arm and study arm respectively. Survival analysis showed that study arm with a prolongation survival trend in OS (mOS: 24.5 months vs. 45.1 months) and disease-free survival (mDFS: 13.4 months vs. 15.4 months). Adverse events (AEs, Grade 1-2) were reported by 67% of patients (44 out of 64). The most frequently reported AEs were anemia (37.5%), leukopenia (7.8%), and diarrhea (4.7%), and there were no differences between the two groups. No Grade 3 or above adverse events were observed.
Conclusions
RPC patients were with a prolongation survival trend by the addition of nimotuzumab into current regimens in the postoperative program with good safety profile.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1624P - Predictive factors for treatment success of second-line Nal-IRI/5-FU/FA in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) (AIO-PAK-0216)
Presenter: Manfred Lutz
Session: Poster session 22
1626P - A novel endoscopic ultrasound guided extended-release siRNA implant targeting KRASG12D/V in localized pancreatic cancer
Presenter: Anna Varghese
Session: Poster session 22
1629P - Modified-FOLFIRINOX-losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: A phase II study
Presenter: Alshaimaa Alhanafy
Session: Poster session 22
1630P - Phase I/Ib study of SHP2-ERK inhibition in KRASm pancreatic cancer (SHERPA trial) and preclinical identification of potential resistance markers
Presenter: Ashwini Cheryl Kanhailal
Session: Poster session 22
1631P - Phase I study of endoscopic ultrasound (EUS)-guided NBTXR3 delivery activated by radiotherapy (RT) for locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC)
Presenter: Gabriela Fuentes
Session: Poster session 22
1632P - Organoids as tools for functional precision oncology in advanced pancreatic cancer
Presenter: Alice Boileve
Session: Poster session 22
1633P - Development and clinical validation of news transcriptomic tools for predicting the response to individual drug of the mfolfirinox regimen in patients with pancreatic ductal adenocarcinoma
Presenter: Nicolas Fraunhoffer
Session: Poster session 22